An investigational gene therapy, EXG001-307, developed by Exegenesis Bio, has shown promising results in improving motor function in a mouse model of spinal muscular atrophy (SMA). Compared to the approved SMA gene therapy Zolgensma, EXG001-307 demonstrated a better safety profile with fewer adverse effects on the animals’ hearts. This allowed for higher doses to be administered, leading to significantly improved survival rates in the study.
SMA, characterized by mutations in the SMN1 gene resulting in reduced SMN protein production, affects motor neuron function and maintenance, leading to loss of specialized nerve cells and SMA symptoms. While only three therapies are approved for SMA treatment, EXG001-307 offers a targeted and safer alternative, utilizing a specific nerve cell promoter to enhance gene activity in neuronal tissue while minimizing protein production in other tissues, potentially improving safety over existing treatments.
In preclinical studies, EXG001-307 demonstrated dose-dependent benefits in increasing body weight, extending survival, and enhancing motor function, strength, and coordination in SMA mice models. The therapy was well tolerated across various doses, showing reduced signs of heart tissue damage and liver toxicity compared to the control treatment. Notably, animals treated with EXG001-307 had improved survival rates and significant motor function gains compared to untreated and control therapy-treated animals.
The study findings suggest that EXG001-307 could address the safety limitations associated with current SMA gene therapies, presenting a strong proof-of-concept for its viability as an effective gene therapy for SMA. Clinical trials in children with SMA type 1 have shown that EXG001-307 is well tolerated and leads to significant improvements in motor development, supporting the continued clinical development of this gene therapy as a safer and more effective treatment for SMA.
Key Takeaways:
– EXG001-307, an investigational gene therapy for SMA, has shown improved motor function and safety profile in preclinical studies.
– The therapy, developed by Exegenesis Bio, offers a targeted approach with potentially fewer adverse effects compared to existing SMA treatments.
– Dose-dependent benefits, enhanced survival rates, and improved motor function were observed in SMA mouse models treated with EXG001-307.
– Clinical trials in SMA type 1 children have demonstrated that EXG001-307 is well tolerated and leads to significant gains in motor development, supporting its potential as a viable gene therapy for SMA.
Tags: gene therapy
Read more on smanewstoday.com